ArticleMetabolites2020
Biotransformation of Silymarin Flavonolignans by Human Fecal Microbiota.
Article in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2024Trial
- Bioactive Plant-Derived Compounds as Novel Perspectives in Oral Cancer Alternative Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Therapeutic potential of flavonoids in gastrointestinal cancer: Focus on signaling pathways and improvement strategies (Review).Molecular medicine reports · 2025Review
- Research progress on the use of polyphenols in the treatment of Crohn's disease.Frontiers in pharmacology · 2025Review
- Mutual Interactions of Silymarin and Colon Microbiota in Healthy Young and Healthy Elder Subjects.Molecular nutrition & food research · 2024Article
- Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.Food science & nutrition · 2024Review
- Modulation of the gut microbiome and Firmicutes phylum reduction by a nutraceutical blend in the obesity mouse model and overweight humans: A double-blind clinical trial.Food science & nutrition · 2024Article
- 7-Antioxidants (Basel, Switzerland) · 2024Article
- Microbially produced vitamin B12 contributes to the lipid-lowering effect of silymarin.Nature communications · 2023Article
- Review
- Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation.Animals : an open access journal from MDPI · 2022Article
- Potential roles of gut microbes in biotransformation of natural products: An overview.Frontiers in microbiology · 2022Review
- Antioxidant Effects and Phytochemical Properties of Seven TaiwaneseMolecules (Basel, Switzerland) · 2021Article
- Metabolism of 2,3-Dehydrosilybin A and 2,3-Dehydrosilybin B: A Study with Human Hepatocytes and Recombinant UDP-Glucuronosyltransferases and Sulfotransferases.Antioxidants (Basel, Switzerland) · 2021Article
- Dose Effect of Milk Thistle (Animals : an open access journal from MDPI · 2021Article
- Identification of Human Sulfotransferases Active towards Silymarin Flavonolignans and Taxifolin.Metabolites · 2020Article
- Naturally Occurring PCSK9 Inhibitors.Nutrients · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Flavonolignans occur typically in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.